Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse

Mammalian Genome

Volumn 25, Issue 9-10, 2014, Pages 473-486

  Riordan, Jesse D ^a   Nadeau, Joseph H ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN;

CYTOPLASM; DISEASE COURSE; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; GENETIC BACKGROUND; HUMAN; LIVER CANCER; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MOUSE; NEGATIVE FEEDBACK; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

EID: 84929511747     PISSN: 09388990     EISSN: 14321777     Source Type: Journal    
DOI: 10.1007/s00335-014-9521-3     Document Type: Review

References (163)

1. Abdelmalek MF et al (2010) Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51(6):1961–1971
2. Aigelsreiter A et al (2012) NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol 43(7):1012–1019
3. Aller EE et al (2011) Starches, sugars and obesity. Nutrients 3(3):341–369
4. Al-Serri A et al (2012) The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56(2):448–454
5. Alwayn IP et al (2005) Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 57(3):445–452
6. An CH et al (2011) Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. Pathol Res Pract 207(7):433–437
7. Anstee QM, Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87(1):1–16
8. Aron-Wisnewsky J et al (2013) Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 19(4):338–348
9. Ascha MS et al (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51(6):1972–1978
10. Attar BM, Van Thiel DH (2013) Current concepts and management approaches in nonalcoholic fatty liver disease. Sci World J 2013:481893
11. Avila MA et al (2000) Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 33(6):907–914
12. Basaranoglu M et al (2013) Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 19(8):1166–1172
13. Betz UA et al (1998) Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 188(10):1955–1965
14. Bozzetto L et al (2012) Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 35(7):1429–1435
15. Browning JD et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6):1387–1395
16. Brunt EM, Tiniakos DG (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16(42):5286–5296
17. Buettner R et al (2007) High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 15(4):798–808
18. Caballero F et al (2010) Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-l-methionine and glutathione. J Biol Chem 285(24):18528–18536
19. Calvisi DF et al (2011) Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140(3):1071–1083
20. Capanni M et al (2006) Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23(8):1143–1151
21. Carulli L et al (2009) Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 41(11):823–828
22. Chalasani N et al (2010) Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139(5):1567–1576 e1561-1566
23. Charlton M et al (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301(5):G825–G834
24. Chattopadhyay M et al (2011) Ablation of PI3K p110-alpha prevents high-fat diet-induced liver steatosis. Diabetes 60(5):1483–1492
25. Chen YM et al (1998) Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int J Cancer 75(5):787–793
26. Chen QR et al (2013a) Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One 8(7):e65982
27. Chen WT et al (2013b) GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene. doi:10.1038/onc.2013.437
28. Collins S et al (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6 J mouse: physiological and molecular characteristics. Physiol Behav 81(2):243–248
29. Cui Y et al (2007) Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 46(2):504–513
30. Czaja MJ et al (1995) Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 108(6):1849–1854
31. Dapito DH et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4):504–516
32. Dela Pena A et al (2005) NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129(5):1663–1674
33. Di Minno MN et al (2012) Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 18(41):5839–5847
34. Domitrovic R et al (2009) Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol Appl Pharmacol 241(3):311–321
35. Dowman JK et al (2014) Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. doi:10.1016/j.ajpath.2014.01.034
36. Ertle J et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128(10):2436–2443
37. Fan CY et al (1996) Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 271(40):24698–24710
38. Fan CY et al (1998) Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273(25):15639–15645
39. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl 1):S99–S112
40. Feldstein AE et al (2005) Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 3(4):384–389
41. Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
42. Ferramosca A et al (2008) Olive oil increases the hepatic triacylglycerol content in mice by a distinct influence on the synthesis and oxidation of fatty acids. Biosci Biotechnol Biochem 72(1):62–69
43. Frau M et al (2012) Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 56(1):165–175
44. Fukuo Y et al (2013) Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. Hepatol Res. doi:10.1111/hepr.12282
45. Gao D et al (2004) Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 287(5):G1070–G1077
46. Garbow JR et al (2011) Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet. Am J Physiol Gastrointest Liver Physiol 300(6):G956–G967
47. Gawrieh S et al (2012) Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci 57(4):952–957
48. Gentile CL et al (2011) Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal 15(2):505–521
49. Goyal R et al (2012) Evaluation of TNF-alpha and IL-6 Levels in obese and non-obese diabetics: pre- and post-insulin effects. N Am J Med Sci 4(4):180–184
50. Guo X et al (2012) Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS One 7(6):e39286
51. Harano Y et al (2006) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26(5):613–620
52. Hashimoto T et al (1999) Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 274(27):19228–19236
53. Hebbard L, George J (2011) Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8(1):35–44
54. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160–171
55. Henkel AS et al (2009) Homocysteine supplementation attenuates the unfolded protein response in a murine nutritional model of steatohepatitis. J Biol Chem 284(46):31807–31816
56. Hill-Baskin AE et al (2009) Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 18(16):2975–2988
57. Ho C et al (2012) AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 55(3):833–845
58. Hollander MC et al (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11(4):289–301
59. Horie Y et al (2004) Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113(12):1774–1783
60. Hosui A et al (2009) Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med 206(4):819–831
61. Huang J et al (2011) Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol 179(2):703–713
62. Huidobro C et al (2013) A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. J Mol Med (Berl) 91(8):939–950
63. Isken F et al (2010) Impairment of fat oxidation under high- vs. low-glycemic index diet occurs before the development of an obese phenotype. Am J Physiol Endocrinol Metab 298(2):E287–E295
64. Kahle M et al (2013) Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis. Mol Metab 2(4):435–446
65. Kudo Y et al (2011) Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol 55(6):1400–1408
66. Lackner C et al (2008) Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 48(5):821–828
67. Laing S et al (2010) Airborne particulate matter selectively activates endoplasmic reticulum stress response in the lung and liver tissues. Am J Physiol Cell Physiol 299(4):C736–C749
68. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28(4):339–350
69. Leamy AK et al (2013) Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52(1):165–174
70. Lee JW et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8):1477–1480
71. Lee JY et al (2011) Dietary oleate has beneficial effects on every step of non-alcoholic Fatty liver disease progression in a methionine- and choline-deficient diet-fed animal model. Diabetes Metab J 35(5):489–496
72. Lee JS et al (2012) Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. Toxicol Lett 211(1):29–38
73. Liu W et al (2006) Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 97(8):768–773
74. Lu SC, Mato JM (2012) S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 92(4):1515–1542
75. Lu SC et al (2001) Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 98(10):5560–5565
76. Luedde T et al (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11(2):119–132
77. Machado RM et al (2010) Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 140(6):1127–1132
78. Malhi H, Kaufman RJ (2011) Endoplasmic reticulum stress in liver disease. J Hepatol 54(4):795–809
79. Marchesini G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8):1844–1850
80. Martinez-Chantar ML et al (2002) Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 16(10):1292–1294
81. Martinez-Chantar ML et al (2008) Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47(4):1191–1199
82. Mathew R et al (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137(6):1062–1075
83. Matsuzawa N et al (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46(5):1392–1403
84. Matthews VB et al (2010) Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53(11):2431–2441
85. Meyer K et al (2003) Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 24(5):975–984
86. Micha R, Mozaffarian D (2009) Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 5(6):335–344
87. Mofrad P et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37(6):1286–1292
88. Montgomery MK et al (2013) Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia 56(5):1129–1139
89. Mueller KM et al (2011) Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 54(4):1398–1409
90. Murphy SK et al (2013) Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145(5):1076–1087
91. Musso G et al (2013) Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr 98(4):895–906
92. Nagarajan P et al (2012) Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World J Gastroenterol 18(11):1141–1153
93. Nakanishi Y et al (2008) Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 38(12):1241–1251
94. Naugler WE et al (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834):121–124
95. Ni M et al (2011) Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 434(2):181–188
96. Nishida T et al (2013) Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Lab Invest 93(2):230–241
97. Nomoto K et al (2006) Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 210(4):469–477
98. Nomura K, Yamanouchi T (2012) The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 23(3):203–208
99. Obara N et al (2010) Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol 53(2):326–334
100. Ono H et al (2003) Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52(12):2905–2913
101. Ouchi N et al (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97
102. Ouyang X et al (2008) Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48(6):993–999
103. Pachikian BD et al (2011) Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS One 6(8):e23365
104. Park JS et al (2013) Gut microbiota and clinical disease: obesity and nonalcoholic fatty liver disease. Pediatr Gastroenterol Hepatol Nutr 16(1):22–27
105. Pellanda H et al (2012) A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma. Int J Biochem Cell Biol 44(2):385–392
106. Penas-Steinhardt A et al (2011) Association of common variants in JAK2 gene with reduced risk of metabolic syndrome and related disorders. BMC Med Genet 12:166
107. Pickens MK et al (2010) Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine–choline-deficient diet. Liver Int 30(8):1229–1239
108. Pogribny IP et al (2013) Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury. FASEB J 27(6):2233–2243
109. Rahman R et al (2013) Primary hepatocellular carcinoma and metabolic syndrome: an update. World J Gastrointest Oncol 5(9):186–194
110. Rebouissou S et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457(7226):200–204
111. Reddy JK et al (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283(5745):397–398
112. Richard J, Lingvay I (2011) Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 9(3):321–328
113. Rinella ME, Green RM (2004) The methionine–choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40(1):47–51
114. Ritze Y et al (2013) Role of serotonin in fatty acid-induced non-alcoholic fatty liver disease in mice. BMC Gastroenterol 13:169
115. Rolo AP et al (2012) Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52(1):59–69
116. Romeo S et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461–1465
117. Roytblat L et al (2000) Raised interleukin-6 levels in obese patients. Obes Res 8(9):673–675
118. Schattenberg JM, Galle PR (2010) Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28(1):247–254
119. Schultz A et al (2013) Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 14(11):21873–21886
120. Sekiya M et al (2003) Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38(6):1529–1539
121. Semba T et al (2013) The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol 13:120
122. Shi SY et al (2012) Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem 287(13):10277–10288
123. Shindo N et al (2010) Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol 52(6):903–912
124. Shockley KR et al (2009) Effects of atherogenic diet on hepatic gene expression across mouse strains. Physiol Genomics 39(3):172–182
125. Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115(24):5651–5661
126. Singh R et al (2009) Autophagy regulates lipid metabolism. Nature 458(7242):1131–1135
127. Soga M et al (1999) The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 49(3):269–275
128. Soga M et al (2003) Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 196(1):43–48
129. Sorrentino P et al (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41(5):751–757
130. Sos BC et al (2011) Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest 121(4):1412–1423
131. Souza MR et al (2012) Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 49(1):89–96
132. Starley BQ et al (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5):1820–1832
133. Stauffer JK et al (2011) Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res 71(7):2718–2727
134. Stiles B et al (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 101(7):2082–2087
135. Streetz KL et al (2003) Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology 125(2):532–543
136. Suzuki W et al (1999) A new mouse model of spontaneous diabetes derived from ddY strain. Exp Anim 48(3):181–189
137. Syn WK et al (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61(9):1323–1329
138. Tailleux A et al (2012) Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821(5):809–818
139. Takahashi Y et al (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18(19):2300–2308
140. Takamura A et al (2011) Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25(8):795–800
141. Tanaka N et al (2008) Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 42(4):413–418
142. Tandra S et al (2011) Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 55(3):654–659
143. Teng YW et al (2011) Deletion of betaine–homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem 286(42):36258–36267
144. Tetri LH et al (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295(5):G987–G995
145. Toshimitsu K et al (2007) Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23(1):46–52
146. Tryndyak V et al (2012) Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism. FASEB J 26(11):4592–4602
147. Vinciguerra M et al (2008) PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134(1):268–280
148. Vuppalanchi R et al (2009) Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7(4):481–486
149. Wahlang B et al (2013) Toxicant-associated steatohepatitis. Toxicol Pathol 41(2):343–360
150. Wang JY et al (1998) Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl4- plus ethanol-induced liver cirrhosis in rats. Liver 18(3):180–185
151. Wang X et al (2014) Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in fatty liver Shionogi mouse. Hepatol Res 44(1):102–113
152. Weber LW et al (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33(2):105–136
153. Yamazaki Y et al (2008) Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J Gastroenterol Hepatol 23(2):276–282
154. Yang ZH et al (2011) Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis 10:120
155. Yessoufou A, Wahli W (2010) Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 140:w13071
156. Yogosawa S et al (2013) Activin receptor-like kinase 7 suppresses lipolysis to accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor gamma and C/EBPalpha. Diabetes 62(1):115–123
157. Yoneda M et al (2008) Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 8:27
158. Yoshimoto S et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499(7456):97–101
159. Yu S et al (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278(1):498–505
160. Yu JH et al (2012) The liver-specific tumor suppressor STAT5 controls expression of the reactive oxygen species-generating enzyme NOX4 and the proapoptotic proteins PUMA and BIM in mice. Hepatology 56(6):2375–2386
161. Zelber-Sagi S et al (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47(5):711–717
162. Zhang XQ et al (2014) Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 20(7):1768–1776
163. Zheng Z et al (2013) Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model. J Hepatol 58(1):148–154